Analyst Ratings For NASDAQ:PBYI – Puma Biotechnology (NASDAQ:PBYI)
Today, Stifel Nicolaus lowered its price target on NASDAQ:PBYI – Puma Biotechnology (NASDAQ:PBYI) to per share.
Some recent analyst ratings include
- 4/12/2018-Barclays was Downgraded by analysts at Barclays from a “Overweight ➝ Equal Weight” rating to a “” rating. They now have a $90.00 price target on the stock.
Recent Insider Trading Activity For NASDAQ:PBYI – Puma Biotechnology (NASDAQ:PBYI)
NASDAQ:PBYI – Puma Biotechnology (NASDAQ:PBYI) has insider ownership of 21.10% and institutional ownership of 97.89%.
- On 1/22/2018 Alan H Auerbach, Insider, sold 10,692 with an average share price of $92.75 per share and the total transaction amounting to $991,683.00.
- On 1/22/2018 Richard Paul Bryce, SVP, sold 1,860 with an average share price of $92.75 per share and the total transaction amounting to $172,515.00.
- On 12/1/2017 Charles R Eyler, Insider, sold 1,322 with an average share price of $105.46 per share and the total transaction amounting to $139,418.12.
- On 9/29/2017 Richard Paul Bryce, SVP, sold 15,000 with an average share price of $120.00 per share and the total transaction amounting to $1,800,000.00.
- On 9/7/2017 Richard Paul Bryce, SVP, sold 15,000 with an average share price of $100.09 per share and the total transaction amounting to $1,501,350.00.
- On 7/20/2017 Alan H Auerbach, Insider, sold 13,175 with an average share price of $94.73 per share and the total transaction amounting to $1,248,067.75.
- On 7/20/2017 Richard Paul Bryce, SVP, sold 1,998 with an average share price of $94.48 per share and the total transaction amounting to $188,771.04.
Recent Trading Activity for NASDAQ:PBYI – Puma Biotechnology (NASDAQ:PBYI)
Shares of NASDAQ:PBYI – Puma Biotechnology closed the previous trading session at with 54.25 shares trading hands.